XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes to the consolidated financial statements - Revenue from contract with customers (Details) - EUR (€)
€ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Notes to the consolidated financial statements    
Revenue recognized € 55,731 € 61,765
Research services combined with an IP license    
Notes to the consolidated financial statements    
Revenue recognized 40,278 49,878
Product    
Notes to the consolidated financial statements    
Revenue recognized 1,413 1,400
Milestone revenues    
Notes to the consolidated financial statements    
Revenue recognized 5,789  
Additional development milestone payments 10,000  
Development milestone payment included in contract liabilities 4,211  
Research and development services    
Notes to the consolidated financial statements    
Revenue recognized 14,040 10,489
Belgium | GSK    
Notes to the consolidated financial statements    
Revenue recognized 52,746 49,621
Germany | Boehringer Ingelheim    
Notes to the consolidated financial statements    
Revenue recognized   9,990
Netherlands | Genmab    
Notes to the consolidated financial statements    
Revenue recognized 1,339 1,323
Switzerland | CRISPR    
Notes to the consolidated financial statements    
Revenue recognized € 1,646 € 831